Hearing LossNCT07526428
Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment
A study testing Phonak Audeo Infinio Hearing Aid and Competitor Device A in people with Hearing Loss, run by Sonova AG at 1 site in United States.
Trial summary
The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are: Do participants correctly identify significantly more words on the AZBio Sentence Test when using Phonak's DNN… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hearing Loss
- What is being tested?
- Phonak Audeo Infinio Hearing Aid and Competitor Device A
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Apr 2026to 19 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults (18+ years old) with audiograms within fitting range of the hearing aid (e.g., moderate to severe sensorineural hearing losses {N3-N5}) and with hearing aid experience will be recruit-ed for this study.
- Ability to fill out questionnaires
- No known cognitive issues.
- Fluent in English, ability to read and write in English.
- Informed consent documented by signature.
- Willingness to wear binaural receiver-in-canal (RIC) devices with domes.
- Willingness to meet up outside of the lab at a local café with two other consented research participants.
Who cannot join
- Contraindications to medical device (MD) in this study: known hypersensitivity or allergy to investigational product/domes.
- Limited mobility/not being able to come to scheduled appoint-ments.
- Limited ability to describe listening impressions/experiences and the use of the hearing aid.
- Known psychological disorders.
Trial locations and contacts
1 site in 1 country.
United States1 site
Phonak Audiology Research Center
Aurora, Illinois, 60504-7940
About this study
The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are:
Do participants correctly identify significantly more words on the AZBio Sentence Test when using Phonak's DNN NR feature than when using Competitor device A in a lab setting? Do participants subjectively rate the speech clarity, ease of listening, and listening confidence higher when using Phonak's DNN feature than when using Competitor device A in both a lab setting and a real-world cafe setting? Do participants have an overall preference for the Phonak device over the Competitor device A in a real-world cafe setting?
Participants will be fit with both the Phonak device and a Competitor device A in the lab. They will be given the AZBio Sentence test and repeat as many words as they can in a simulated noisy environment. Following the lab visit, participants will meet in a group with three other conversation partners in a real-world setting and asked to complete subjective questionnaires during the visit.
Read the detailed description
Participants will undergo a hearing aid fitting for both the Phonak device and the Competitor device A. In the lab, participants will be seated in the center of a 10-speaker array. Diffuse ecologically valid noise will be coming from all 10 speakers, while recorded sentences will be presented one at a time randomly from 4 speakers in front of the participant. Participants will be given two lists of 25 sentences for each hearing aid condition, and will repeat as many words as they can. Percentage correct will be calculated for each hearing aid condition. The second appointment will consist of a real-world visit to a local cafe, in which they will be seated at a table with three other conversation partners. During the cafe visit, participants will be asked to answer questions about their perceived speech clarity, ease of listening, and listening confidence with each of the two devices. Participants will be blinded as to which devices they are wearing for both the lab visit and the real world cafe visit.
- Conditions
- Hearing Loss
- Being tested
- Phonak Audeo Infinio Hearing Aid, Competitor Device A
- Medical subject headings
- Hearing Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Phonak Audeo Infinio Hearing AidDevice
Phonak Audeo Infinio RIC
Competitor Device ADevice
Competitor Device A
| Study group | Role | What they receive |
|---|---|---|
| Participants fit and tested with the Phonak device first, then the Competitor device A. | Experimental | Participants that are tested first with the Phonak device, and then with the Competitor device A. Receives: Device: Phonak Audeo Infinio Hearing Aid; Device: Competitor Device A |
| Participants fit and tested with Competitor device A first, then with Phonak device. | Experimental | Participants that are tested first with the Competitor device A, then with the Phonak device. Receives: Device: Phonak Audeo Infinio Hearing Aid; Device: Competitor Device A |
What is being measured
The primary outcome is the main question the study is designed to answer.
AZBio Sentence Test
A validated speech perception test consisting of 25 different lists of sentences. Sentences are presented via a loudspeaker at a pre-determined level and the number of words correctly repeated are calculated into a percenteage. The higher the percentage, the better the participant's speech perception.
Measured: Day 1 of study
Secondary outcomes (1)
Composite Questionnaire
A 5-point Likert scale questionnaire that asks participants to rate the speech clarity, ease of listening, and listening confidence for each hearing aid. The scale is from 1 = Strongly disagree, to 5 = Strongly agree. Participants will be given this questionnaire following the AZBio Sentence test in the lab, and following the group conversation in the cafe.
Measured: Days 1 and 2 of study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start9 Apr 2026
- Primary completion19 Apr 2026
- Study completion19 Apr 2026
Why it stopped: Corrupted data
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hearing LossStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sonova AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07526428
- Sponsor's protocol ID
- SRF-36296
- Status last verified
- May 2026
- First submitted
- 6 Apr 2026
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment
- ClinicalTrials.gov ID
- NCT07526428
- Acronym / sponsor ID
- SRF-36296
- Conditions
- Hearing Loss
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Corrupted data
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Sonova AGIndustry (pharma, biotech, devices)
- Study start
- 9 Apr 2026 (actual)
- Primary completion
- 19 Apr 2026 (actual)
- Study completion
- 19 Apr 2026 (actual)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are:
Do participants correctly identify significantly more words on the AZBio Sentence Test when using Phonak's DNN NR feature than when using Competitor device A in a lab setting? Do participants subjectively rate the speech clarity, ease of listening, and listening confidence higher when using Phonak's DNN feature than when using Competitor device A in both a lab setting and a real-world cafe setting? Do participants have an overall preference for the Phonak device over the Competitor device A in a real-world cafe setting?
Participants will be fit with both the Phonak device and a Competitor device A in the lab. They will be given the AZBio Sentence test and repeat as many words as they can in a simulated noisy environment. Following the lab visit, participants will meet in a group with three other conversation partners in a real-world setting and asked to complete subjective questionnaires during the visit.
Detailed description
Participants will undergo a hearing aid fitting for both the Phonak device and the Competitor device A. In the lab, participants will be seated in the center of a 10-speaker array. Diffuse ecologically valid noise will be coming from all 10 speakers, while recorded sentences will be presented one at a time randomly from 4 speakers in front of the participant. Participants will be given two lists of 25 sentences for each hearing aid condition, and will repeat as many words as they can. Percentage correct will be calculated for each hearing aid condition. The second appointment will consist of a real-world visit to a local cafe, in which they will be seated at a table with three other conversation partners. During the cafe visit, participants will be asked to answer questions about their perceived speech clarity, ease of listening, and listening confidence with each of the two devices. Participants will be blinded as to which devices they are wearing for both the lab visit and the real world cafe visit.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Participants fit and tested with the Phonak device first, then the Competitor device A. | Experimental | Device: Phonak Audeo Infinio Hearing Aid, Device: Competitor Device AParticipants that are tested first with the Phonak device, and then with the Competitor device A. |
| Participants fit and tested with Competitor device A first, then with Phonak device. | Experimental | Device: Phonak Audeo Infinio Hearing Aid, Device: Competitor Device AParticipants that are tested first with the Competitor device A, then with the Phonak device. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults (18+ years old) with audiograms within fitting range of the hearing aid (e.g., moderate to severe sensorineural hearing losses {N3-N5}) and with hearing aid experience will be recruit-ed for this study.
- Ability to fill out questionnaires
- No known cognitive issues.
- Fluent in English, ability to read and write in English.
- Informed consent documented by signature.
Key exclusion criteria (4 listed)
- Contraindications to medical device (MD) in this study: known hypersensitivity or allergy to investigational product/domes.
- Limited mobility/not being able to come to scheduled appoint-ments.
- Limited ability to describe listening impressions/experiences and the use of the hearing aid.
- Known psychological disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Phonak Audeo Infinio Hearing AidPhonak Audeo Infinio RIC | Device | Participants fit and tested with Competitor device A first, then with Phonak device., Participants fit and tested with the Phonak device first, then the Competitor device A. |
| Competitor Device ACompetitor Device A | Device | Participants fit and tested with Competitor device A first, then with Phonak device., Participants fit and tested with the Phonak device first, then the Competitor device A. |
Primary outcome
AZBio Sentence Test
Time frame: Day 1 of study
A validated speech perception test consisting of 25 different lists of sentences. Sentences are presented via a loudspeaker at a pre-determined level and the number of words correctly repeated are calculated into a percenteage. The higher the percentage, the better the participant's speech perception.
1 secondary outcome
Composite Questionnaire
Time frame: Days 1 and 2 of study
Results and safety
The study was stopped early (reason given: Corrupted data). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: No
Related trials for Hearing Loss
RecruitingObservational study
Impact of Vestibular Function on Deaf Infants' Activities of Daily Living
Vestibular Dysfunction, Hearing Loss
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
Not yet recruiting
Hearing Intervention Effects on Brain and Language Development in Children With Bilateral Mild Hearing Loss
Hearing Loss, Bilateral
RecruitingObservational study
Natural History of Autosomal Dominant Hearing Loss
Hearing Loss
RecruitingObservational study
Retrospective Analysis of Speech Performance Using the HiRes Ultra and HiRes Ultra 3D Cochlear Implant
Cochlear Hearing Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Phonak Audeo Infinio Hearing Aid and Competitor Device A in people with Hearing Loss, run by Sonova AG at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Corrupted data). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AZBio Sentence Test (time frame: Day 1 of study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.